Clinical Trials Browser

Phase 1/2 × INDUSTRY × Inotuzumab Ozogamicin × Clear all

NCT00299494 2018-03-08

Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)

Phase 1/2 Completed

119 enrolled 60 charts

Lymphoma, Lymphoma, B-Cell